NRC National Research: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

National Research (NRC) leverages a cloud-based SaaS infrastructure to optimize medical data flows, ensuring high reliability and profitability. The business successfully bypasses geopolitical barriers by focusing on protected US markets. This chart of EPS (TTM) price action currently stands at -60.10. However, challenges may arise due to reductions in government spending on analytics and pressure from integrated IT products.

National Research monetizes mandatory US healthcare quality requirements through SaaS platforms and AI-driven patient loyalty analysis. The dynamics of these recurring revenues are digitized via the rate of change in rolling net earnings per share, recorded at -60.10. This metric measures the profit growth rate relative to the previous year, revealing the efficiency of business scaling. By analyzing the current EPS YoY shift over the last 12 months, an investor can determine the growth phase or the risk of exhausted drivers.